Essential Thrombocythemia Clinical Trial
Official title:
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: - The safety and tolerability of Bomedemstat - The pharmacodynamic effect of Bomedemstat
Status | Completed |
Enrollment | 73 |
Est. completion date | March 23, 2023 |
Est. primary completion date | March 23, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms. - Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis. - Have failed at least one standard therapy - Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation. Exclusion Criteria: - Has undergone major surgery =4 weeks prior to starting study drug or has not recovered from side effects of such surgery. - Unresolved treatment related toxicities from prior therapies (unless resolved to = Grade 1). - Uncontrolled active infection. - Current use of prohibited medications - Known HIV infection or active Hepatitis B or Hepatitis C virus infection - Other hematologic/biochemistry requirements, as per protocol - Use of investigational agent within last 14 days - Pregnant or lactating females |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Local Institution | Camperdown | New South Wales |
Australia | Local Institution | Clayton | Victoria |
Australia | Local Institution | Herston | Brisbane |
Australia | Local Institution | Southport | Queensland |
Australia | Local Institution | St Leonards | New South Wales |
Germany | Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ) | Essen | |
Germany | Local Institution | Jena | |
Hong Kong | Local Institution | Hong Kong | |
Italy | Local Institution | Alessandria | |
Italy | Local Institution | Bologna | |
Italy | CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi | Florence | |
Italy | Local Institution | Varese | |
New Zealand | Local Institution | Auckland | |
New Zealand | Middlemore Hospital | Auckland | |
United Kingdom | Guys and St Thomas Hospital | London | |
United Kingdom | Local Institution | London | |
United Kingdom | Local Institution | London | |
United Kingdom | Local Institution | Oxford | |
United States | Local Institution | Ann Arbor | Michigan |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Local Institution | Durham | North Carolina |
United States | Local Institution | Jacksonville | Florida |
United States | Local Institution | New York | New York |
United States | Local Institution | Pittsburgh | Pennsylvania |
United States | Local Institution | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) |
United States, Australia, Germany, Hong Kong, Italy, New Zealand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Experienced an Adverse Event (AE) | An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported. | Up to approximately 30 months | |
Primary | Number of Participants Who Discontinued Study Treatment Due to an AE | An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported. | Up to approximately 28 months | |
Primary | Percentage of Participants With Platelet Count =400 k/µL at Day 169 | Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to =400k/µL in the absence of new thrombolytic events is reported. | Up to day 169 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05482971 -
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
|
Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
Completed |
NCT00666549 -
Research Tissue Bank
|
||
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01192347 -
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
|
||
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Recruiting |
NCT04942080 -
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
|
N/A | |
Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Active, not recruiting |
NCT04262141 -
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
|
Phase 2 | |
Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
Active, not recruiting |
NCT00588991 -
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
|
Phase 1 | |
Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
Completed |
NCT01787552 -
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03116542 -
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
|
N/A | |
Recruiting |
NCT06361641 -
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
|
N/A | |
Recruiting |
NCT06378437 -
A Study of GLB-001 in Patients With Myeloid Malignancies
|
Phase 1 | |
Recruiting |
NCT05882773 -
Asian Myeloproliferative Neoplasm (MPN) Registry
|
||
Completed |
NCT02129101 -
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
|
Phase 1 | |
Completed |
NCT00357305 -
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
|
Phase 1 |